Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12750MR)

This product GTTS-WQ12750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12750MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7046MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ4653MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ13029MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4265MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ15039MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ14438MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ1273MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW